Myriad Publishes Clinical Utility Study for Prolaris(R)

[at noodls] – SALT LAKE CITY, March 3, 2014 (GLOBE NEWSWIRE) — Myriad Genetics, Inc. (Nasdaq:MYGN) today announced that it has published data from the PROCEDE 500 study in the journal Current Medical Research and Opinion, … more

View todays social media effects on MYGN

View the latest stocks trending across Twitter. Click to view dashboard

See who Myriad is hiring next, click here to view